Author(s)

Firmin Bossali¹, G. Ndziessi², G. Deby³, C. R. Ahoui Apendi³, J. F. Mimiesse³, B. I. Atipo-Ibara³, J. R. Ibara³

¹Gastroenterology Department, General Hospital of Loandjili, Pointe-Noire, Congo.
²Faculty of Health Sciences, Brazzaville, Congo.
³Gastroenterology Department-CHU, Brazzaville, Congo.

Current antiretroviral therapy has reduced morbidity and mortality of HIV patients. However, their induced hepatotoxicity constitutes a risk. In this issue, we report a clinical case of fulminant hepatitis, observed in the HIV unit of the hepatogastroenterology department of the General hospital of Loandjili in Pointe-Noire. The patient is a 36-year-old female HIV treated with triple-dug combination antiretroviral therapies (ART) including one antiprotease (ritonavir) and two non-nucleoside reverse transcriptase inhibitors (nevirapine and efavirenz). He developed fulminant hepatitis five years after treatment initiation. He succumbed to the side effects. Although antiretroviral combination therapies are the standard of care for HIV infection, increased vigilance is warranted to early identify this side effect and adjust treatment in order to prevent fatal consequences.

Fulminant Hepatitis, Hepatotoxicity, Antiretroviral Therapy, Pointe-Noire

Bossali, F. , Ndziessi, G. , Deby, G. , R. Ahoui Apendi, C. , F. Mimiesse, J. , I. Atipo-Ibara, B. and R. Ibara, J. (2018) Fulminant Hepatitis Following Ritonavir-Nevirapine-Efavirenz Regimen in a Female HIV Patient in Pointe-Noire in 2016. Open Journal of Gastroenterology, 8, 167-171. doi: 10.4236/ojgas.2018.85019.